Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5,439 | $4,019 | $3,916 | $5,124 |
| % Growth | 35.3% | 2.6% | -23.6% | – |
| Cost of Goods Sold | $128 | $214 | $285 | $365 |
| Gross Profit | $5,311 | $3,805 | $3,631 | $4,759 |
| % Margin | 97.7% | 94.7% | 92.7% | 92.9% |
| R&D Expenses | $14,404 | $18,644 | $13,199 | $14,746 |
| G&A Expenses | $5,481 | $4,772 | $4,988 | $5,435 |
| SG&A Expenses | $5,481 | $4,763 | $5,039 | $5,514 |
| Sales & Mktg Exp. | $0 | -$10 | $51 | $79 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,886 | $23,407 | $18,238 | $20,260 |
| Operating Income | -$14,574 | -$19,602 | -$14,636 | -$15,502 |
| % Margin | -268% | -487.7% | -373.7% | -302.6% |
| Other Income/Exp. Net | $2,495 | $524 | $905 | $2,724 |
| Pre-Tax Income | -$12,080 | -$19,077 | -$13,702 | -$12,777 |
| Tax Expense | $68 | $46 | $104 | $70 |
| Net Income | -$12,148 | -$19,123 | -$13,807 | -$12,847 |
| % Margin | -223.4% | -475.8% | -352.5% | -250.7% |
| EPS | -1.14 | -3.12 | -3.42 | -3.18 |
| % Growth | 63.5% | 8.8% | -7.5% | – |
| EPS Diluted | -1.14 | -3.12 | -3.42 | -3.18 |
| Weighted Avg Shares Out | 10,662 | 6,083 | 4,046 | 4,010 |
| Weighted Avg Shares Out Dil | 10,662 | 6,081 | 4,046 | 4,010 |
| Supplemental Information | – | – | – | – |
| Interest Income | $446 | $268 | $16 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $28 | $35 | $38 | $54 |
| EBITDA | -$14,633 | -$19,572 | -$14,598 | -$17,392 |
| % Margin | -269% | -486.9% | -372.8% | -339.5% |